MedTrace Logo

Prospective Breast Cancer Biobanking

NCT04488614 · Status: ENROLLING_BY_INVITATION · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2020-07-30

No results posted yet for this study

Summary

Prospective Breast Cancer Biobanking study (PBCB) will apply advanced monitoring in liquid biopsies of early staged breast cancer ration in order to facilitate A. Early detection of systemic relapses B.Improve adherence and drug monitoring av tamoxifen treatment C. Tumour microenvironment in breast cancer - adipose stromal immune infiltration and interaction with tumour at the growth zone D.Monitor side effects, QoL, depression, fatigue and work life participation

Conditions

Interventions

PROCEDURE

Breast Concervative or Meastectomy

National treatment guidelines in Norway

Sponsors & Collaborators

  • Helse-Bergen HF

    collaborator OTHER

  • Helse Stavanger HF

    lead OTHER_GOV

Principal Investigators

  • Gunnar Mellgren, PhD · Helse Bergen HF; Haukeland University Hospital

  • Håvard Søiland, PhD · Helse Stavanger HF; Stavanger University Hospital

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-01
Primary Completion
2022-07-15
Completion
2030-07-15

Countries

  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04488614 on ClinicalTrials.gov